Wall Street brokerages expect Urogen Pharma (NASDAQ:URGN) to announce earnings of ($0.05) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Urogen Pharma’s earnings, with the lowest EPS estimate coming in at ($0.46) and the highest estimate coming in at $0.10. The company is expected to announce its next earnings results on Monday, November 13th.
According to Zacks, analysts expect that Urogen Pharma will report full year earnings of ($2.15) per share for the current fiscal year, with EPS estimates ranging from ($2.74) to ($1.76). For the next year, analysts anticipate that the business will report earnings of ($2.89) per share, with EPS estimates ranging from ($4.19) to ($1.76). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Urogen Pharma.
URGN has been the topic of a number of recent analyst reports. Oppenheimer Holdings, Inc. initiated coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They issued an “outperform” rating and a $32.00 target price on the stock. Jefferies Group LLC initiated coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They issued a “buy” rating and a $27.00 target price on the stock. Cowen and Company initiated coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They issued an “outperform” rating on the stock. Raymond James Financial, Inc. initiated coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They issued an “outperform” rating and a $25.00 target price on the stock. Finally, Zacks Investment Research raised shares of Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Wednesday, August 2nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $26.00.
Urogen Pharma (NASDAQ URGN) traded up 0.58% on Friday, reaching $17.47. 28,315 shares of the company’s stock were exchanged. The firm’s market cap is $227.27 million. Urogen Pharma has a 12 month low of $13.01 and a 12 month high of $20.02. The firm’s 50-day moving average is $18.16 and its 200-day moving average is $17.58.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Spark Investment Management LLC acquired a new position in shares of Urogen Pharma during the second quarter worth approximately $856,000. Menora Mivtachim Holdings LTD. acquired a new position in shares of Urogen Pharma during the second quarter worth approximately $2,331,000. LLBH Private Wealth Management LLC acquired a new position in shares of Urogen Pharma during the second quarter worth approximately $695,000. Alps Advisors Inc. acquired a new position in shares of Urogen Pharma during the second quarter worth approximately $195,000. Finally, Jennison Associates LLC acquired a new position in shares of Urogen Pharma during the second quarter worth approximately $3,168,000. Institutional investors and hedge funds own 3.59% of the company’s stock.
About Urogen Pharma
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Get a free copy of the Zacks research report on Urogen Pharma (URGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
